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Abstract
It is now well established that the utilization of standardized clinical criteria can enhance 
prediction of psychosis. These criteria are primarily concerned with the presence and severity of 
attenuated positive symptoms. Because these symptom criteria are used to derive algorithms for 
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designating clinical high risk (CHR) status and for maximizing prediction of psychosis risk, it is 
important to know whether the symptom ratings vary as a function of demographic factors that 
have previously been linked with symptoms in diagnosed psychotic patients. Using a sample of 
356 CHR individuals from the NAPLS-II multi-site study, we examined the relation of three sex, 
age, and educational level, with the severity of attenuated positive symptom scores from the Scale 
of Prodromal Symptoms (SOPS). Demographic factors accounted for little of the variance in 
symptom ratings (5–6%). Older CHR individuals manifested more severe suspiciousness, and 
female CHR participants reported more unusual perceptual experiences than male participants. 
Contrary to prediction, higher educational level was associated with more severe ratings of 
unusual thought content, but less severe perceptual abnormalities. Overall, sex, age and education 
were modestly related to unusual thought content and perceptual abnormalities, only, suggesting 
minimal implication for designating CHR status and predicting psychosis-risk.
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1. Introduction
Extensive research efforts have aimed to understand the causes of schizophrenia and other 
psychotic disorders, yet the etiological determinants remain largely unknown (Jablensky, 
1997). The past decade has been marked by an increased interest in the period of functional 
decline preceding the clinical onset of psychosis, and this shift in focus has been 
accompanied by efforts to enhance prospective risk prediction. This period is referred to as 
the prodrome, and it can last from months to several years (Addington and Heinssen, 2012). 
Individuals with symptoms characteristic of a prodromal state are often designated as 
“clinical high risk” (CHR). Characterizing the phenomenology in this period and optimizing 
clinical prediction of risk for conversion to psychosis are top priorities.
It has been demonstrated that individuals who meet standardized criteria for measuring 
prodromal signs are at a significantly elevated risk for developing a psychotic disorder 
within a few years following baseline assessment (Cannon et al., 2008; Nelson et al., 2013; 
Ruhrmann et al., 2010). In particular, ratings of the severity of attenuated positive psychotic 
symptoms enhance prediction of subsequent psychosis with noteworthy sensitivity and 
specificity (Cannon et al., 2008). It is assumed that future refinements of clinical algorithms, 
as well as the addition of biomarkers, will further enhance prediction and targeted 
preventive interventions.
It is well-established that demographic factors are associated with both the clinical 
presentation and progression of psychosis; sex, age, and education level have well-replicated 
relationships with schizophrenia-spectrum risk rates and symptoms (Choi et al., 2009; 
Moukas et al., 2010; Willhite et al., 2008). The aim of the current study is to characterize the 
nature of the relationship between these demographic factors and positive symptoms in CHR 
individuals to improve prediction of subsequent psychosis, as optimal prediction algorithms 
may vary as a function of demographic factors. Previous studies of high-risk individuals 
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suggest that age and sex are not associated with conversion to psychosis (Cannon et al., 
2008; Nelson et al., 2013; Schultze-Lutter et al., 2007; Velthorst et al., 2009; Ziermans et al., 
2011). Outcomes regarding education, however, are mixed with some finding associations 
with conversion (Ruhrmann et al., 2010; Schultze-Lutter et al., 2007) and others not (Mason 
et al., 2004). The current paper aims to explore demographic predictors with specific 
positive symptoms, the primary determinants of conversion status. If a pattern of symptom 
presentation can be gleaned, including demographically-related protective factors, there will 
be significant implications for targeted intervention.
1.1. Sex differences
Research on sex differences across the schizophrenia-spectrum has examined the 
development, functional impairments, and course of these illnesses. The most well-
replicated symptom trends are sex differences in symptom severity; males tend to exhibit 
greater thought disorder than females (Gur et al., 1996; Thorup et al., 2007a,b), whereas 
females tend to endorse more auditory hallucinations (Marneros, 1984; Rector and Seeman, 
1992; Sharma et al., 1999; Tang et al., 2007; Thorup et al., 2007a,b), paranoia, and 
persecutory delusions (Andia et al., 1995; Goldstein and Link, 1988; Räsänen et al., 2000; 
Tang et al., 2007). Although research examining sex differences in CHR samples is limited, 
the findings to date are consistent with those on schizophrenia; CHR females exhibit greater 
magical thinking and auditory hypersensitivity (Moukas et al., 2010).
1.2. Age
The modal age range for psychosis onset reflects an earlier age of onset (18–25 years) in 
males compared to females (25–35 years) (Goldstein et al., 1989; Gureje, 1991; Thorup et 
al., 2007a,b). Evidence suggests that psychosis onset before age 18 is associated with a more 
chronic illness course, more severe psychotic symptoms and more severe cognitive 
impairments (de Girolamo et al., 2012; Mirzakhanian et al., 2013; Walker et al., 2004; Yung 
et al., 2007). In CHR populations, younger age at onset of CHR syndromes is associated 
with higher transition rates to psychosis (Yung et al., 2007) and reports of more severe odd 
beliefs, delusions of reference, unusual perceptions, odd behavior, auditory hallucinations, 
and physical anhedonia (Bora and Arabaci, 2009; Paino-Pineiro et al., 2008).
1.3. Education
Level of education is most often reported only as a sample characteristic, rather than a 
variable relevant to illness presentation. Yet, studies of the relation of education with 
symptom presentation in schizophrenia-spectrum disorders indicate that lower education is 
associated with more negative symptoms (McGlashan and Fenton, 1992) and poorer 
prognoses (Wieselgren and Lindstrom, 1996). Studies of those with psychosis have also 
found that completion of high school (Austin et al., 2013) and generally achieving higher 
levels of education (Chang et al., 2012; Verma et al., 2012) are predictive of recovery from 
psychotic illness. Ruhrmann et al. (2010) demonstrated that lower education was a 
significant predictor of conversion to psychosis in a CHR sample.
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1.4. The present study
The North American Prodrome Long itudinal Study (NAPLS) is a multisite study aimed at 
identifying predictors of the transition to psychosis. NAPLS has a large database of 
longitudinally followed CHR cases and provides a unique opportunity to examine 
demographic correlates of symptoms. The present study utilizes the NAPLS-II CHR cohort 
and focuses on the five SOPS positive prodromal symptoms; unusual thought content, 
suspiciousness, grandiosity, perceptual abnormalities, and disorganized communication. Our 
focus is restricted to the positive symptom domain because it is primarily the severity of 
these symptoms that determines whether individuals are designated as being at CHR for 
psychosis.
Based on the literature, it is hypothesized that males will demonstrate more disorganized 
communication, and females will manifest more severe perceptual abnormalities, and 
suspiciousness. Further, it is hypothesized that younger individuals will exhibit more severe 
positive symptoms and educational level will be inversely correlated with symptom severity.
2. Method
2.1. Participants
The current sample, recruited for the NAPLS-II study includes 356 CHR individuals. 
Sample demographic characteristics are presented in Table 1. Participants were excluded 
from NAPLS-II if at baseline they 1.) met DSM-IV criteria for an Axis I psychotic disorder; 
2.) experienced a significant head injury; 3.) met substance dependence criteria within the 
past 6 months; 4.) had a neurological disorder; or 5.) had a Full Scale IQ <70. More detailed 
information on the CHR sample is presented in previous reports (Addington and Heinssen, 
2012; Addington et al., 2012). Participants were recruited from clinical practitioners as well 
as newspaper, bus, and online announcements. The current protocol was approved by 
Institutional Review Boards at all NAPLS sites, and all participants provided informed 
consent for minors.
2.2. Measures
2.2.1. Prodromal symptomatology—Participants were designated as CHR using the 
Structured Interview for Prodromal Syndromes (SIPS, Miller et al., 2003). Interview 
responses were scored by trained interviewers on the Scale of Prodromal Symptoms (SOPS, 
Miller et al., 2003). The SOPS provides an index of symptom severity that ranges from 0 
(absent) to 6 (psychotic) for five symptom domains: unusual thought content, 
suspiciousness, grandiosity, perceptual abnormalities, and disorganized communication. See 
Miller et al. (2003) for a detailed description of the five positive symptom categories and 
SOPS diagnostic criteria for a prodromal syndrome.
2.3. Procedures
At each NAPLS site an initial screening interview was conducted to ensure that the 
individuals met prodromal criteria on the SOPS. Assessments were conducted by trained 
interviewers who met reliability standards (Addington et al., 2012). Cross-site reliability in 
symptom ratings was established before study initiation and on a yearly basis. The kappa 
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statistic was used to compare interviewer agreement with the gold standard diagnosis on the 
SOPS ratings. Within all sites, intra-class correlations exceeded .80.
2.4. Data analyses
Correlation and ordinal logistic regression analyses were conducted to explore relationships 
between demographic variables and SOPS scores. Medication status (on medication versus 
not on medication) was also included as a predictor in the regression analyses as an index of 
symptom severity.
3. Results
Pearson and point-biserial (1 = male, 2 = female) correlation coefficients relating the 
positive symptom scores and demographic variables are presented in Table 2. The severity 
ratings of all of the symptoms are positively, and in most cases significantly, inter-
correlated. Additional correlations for demographic variables and SOPS scores were modest. 
Female sex and lower educational level were significantly associated with more severe 
perceptual abnormalities, and older age was associated with greater suspiciousness. Age and 
education were significantly positively inter-correlated. Sex was unrelated to age or 
educational level. Independent samples t-tests were conducted for sex and each of the 
predictor and outcome variables. There were no significant sex differences for age, 
education, medication status, and SOPS symptoms.
Ordinal logistic regression analyses were conducted separately for each of the five positive 
symptom indices. In each regression analysis the positive symptom score (P1–P5) was 
entered as the dependent variable and age, sex, years of education, and medication status 
(i.e. antidepressants, antipsychotics, stimulants, mood stabilizers) were entered as predictor 
variables. The models were significant for P1 (unusual thought content), P4 (perceptual 
abnormalities), and P5 (disorganized communication) symptom domains. See Table 3 for 
the model and parameter estimates for the SOPS symptoms.
The overall effect of the demographic variables on P1 symptoms accounted for 5% of the 
variance in symptom severity. Of the predictors only age (Wald χ2=12.4, p < 0.001) and 
education (Wald χ2=12.7, p < 0.001) were significant. Age was inversely related to P1 
symptom severity; younger CHR individuals were more likely to have higher symptom 
ratings. Conversely, years of education were positively associated with P1 symptom 
severity; CHR individuals with higher levels of education were more likely to have higher 
symptom ratings.
The overall effect of the demographic variables on P4 symptoms accounted for 6% of the 
variance in symptom severity. Sex (Wald χ2 = 7.7, p < 0.01), education (Wald χ2 = 3.4, p < .
05), and stimulant medication (Wald χ2 = 4.5, p < .05) were significant predictors. Females 
were more likely to have higher symptom ratings. Education was inversely related to 
symptom severity, such that individuals with fewer years of education were more likely to 
have higher symptom ratings. Finally, CHR individuals who were taking stimulant 
medication at the time of the assessment were more likely to have higher symptom ratings.
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Finally, while the model was not significant for P5, mood stabilizers emerged as a 
significant predictor. CHR individuals taking mood stabilizers at baseline were more likely 
to have higher symptom ratings (Wald χ2 = 4.9, p < 0.05).
Ordinal regression analyses were run separately by sex for P4 symptoms to explore the 
significant sex effect found in the first model. Similar to the main model, symptom ratings 
were entered as the dependent variable and age, education, and medication status were 
entered as predictors. The overall effect of demographic variables on P4 was not significant 
for either females or males. However, for males, education (β = −.19, Wald χ2 = 5.6, p < .
05), was a significant predictor and showed an inverse relationship with symptom severity.
4. Discussion
The present study examined the relationship of demographic factors with positive symptom 
severity in a CHR sample meeting criteria for a prodromal syndrome. The present analyses 
revealed that sex, age and education were modestly related to unusual thought content and 
perceptual abnormalities. While similar findings have been yielded from other studies and 
research groups (EPOS, Ruhrmann et al., 2010; PACE, Nelson et al., 2013; FETZ, Schultze-
Lutter et al., 2007) further exploration is warranted. Some variation in inclusion and 
exclusion exists across research groups, reflecting somewhat different cohorts. Moreover, 
previous finding regarding positive symptoms have used a composite score or conversion 
status; to our knowledge no previous study has examined positive SOPS symptoms, 
individually.
Age was a significant inverse predictor of unusual thought content. This finding is consistent 
with previous work showing that younger psychotic patients have more severe symptoms in 
general (de Girolamo et al., 2012; Mirzakhanian et al., 2013; Walker et al., 2004; Yung et 
al., 2007). This may be due, in part, to the adverse impact of the disease process on 
developing cognitive capacities. Also, younger CHR participants may have less ability to 
reason through and discount unusual ideations.
Sex was significantly associated with perceptual abnormalities; females were more likely to 
have severe ratings than males. Again, this finding is consistent with past reports that 
females diagnosed with psychosis manifest more severe auditory hallucinations (Marneros, 
1984; Rector and Seeman, 1992; Sharma et al., 1999; Tang et al., 2007; Thorup et al., 
2007a,b). However, the proportion of the variance in severity of perceptual abnormalities 
that was accounted for by sex was very small.
Education yielded a varied pattern of results. While our predictions held for perceptual 
abnormalities, in that this symptom was more likely to be more severe in those with lower 
education (Ruhrmann et al., 2010; Wieselgren and Lindstrom, 1996), the opposite was found 
for unusual thought content. The literature regarding the independent role of education in the 
presentation of individual positive symptoms is sparse. In general, the available literature 
suggests that higher levels of education can be protective due to greater cognitive resources 
and more advanced coping strategies (Austin et al., 2013; Chang et al., 2012; Jonsson and 
Nyman, 1984; Verma et al., 2012; Wieselgren and Lindstrom, 1996). It has also been 
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suggested, however, that greater abstract thinking ability may intensify the presentation of 
some ideational psychotic processes (Chen et al., 1997).
Further exploration of the sex effects found for perceptual abnormalities revealed that males' 
educational experience characterized the relationship between education and greater 
likelihood of higher ratings of perceptual abnormalities. Thus, continued educational and 
academic supports in males may be particularly critical when attenuated symptoms are 
beginning to develop and/or other risk factors have been identified.
Psychotropic medication was not an exclusion criterion in the present study, yet the 
proportion of medicated CHR individuals was small (see Woods et al., 2013). Analyses 
revealed higher ratings individuals taking stimulants at baseline were more likely to report 
perceptual abnormalities, and individuals taking mood stabilizers at baseline were more 
likely to endorse and demonstrate higher disorganized scores. Increased SOPS ratings for 
individuals taking medication is not surprising given that treatment providers are more likely 
to prescribe psychotropics when symptoms are more severe. Moreover, stimulants have been 
shown to exacerbate attenuated and clinically significant psychotic symptoms (Sharma et al., 
1991). Because these analyses are based on naturalistic data, causal inferences cannot be 
drawn; medication status can be precipitated by symptom severity and can also affect 
symptom severity. Nonetheless, the results of these analyses indicate that the effects of 
medication status on symptom severity are modest.
4.1. Limitations
A limitation of the present study is that sample selection criteria can attenuate the relation 
between symptom severity ratings and other measures, including demographic factors. CHR 
individuals are recruited based on the presence of symptoms that fall within predetermined 
severity windows. As noted, the SOPS utilizes a 6 point scale to rate all symptoms, and 
designation as CHR requires that the individual manifest a score of 3 to 5 on at least one of 
the attenuated positive symptoms on the SOPS. At the upper end of the scale, if the 
individual has a score of 6 (psychosis) on any positive symptom, they are excluded from the 
sample. As a result, the SOPS, by intention, yields CHR samples that manifest a restricted 
range of baseline scores on the positive symptom ratings, but not the other symptom 
domains. Thus, a restricted range of scores will reduce variability and constrain the 
magnitude of the correlations obtained between the positive symptoms and other measures. 
The present estimates of the relation between demographic factors and symptom severity 
hold only for CHR-designated samples.
A second limitation of the current study is that some participants were on psychotropic 
medication at baseline. Our analyses indicate that the relation of medication with symptom 
severity ratings is modest, and only reaches significance for stimulants and mood stabilizers. 
Moreover, excluding those on medication would result in a non-representative sample of 
CHR individuals (Woods et al., 2013).
4.2. Summary and future directions
While the present study indicates that demographic factors are associated with ratings of 
some positive symptoms in CHR individuals, overall they account for very little of the 
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variance. The findings suggest that demographic factors are not influencing prodromal 
symptom presentation in a manner that would alter detection of CHR syndromes as a 
function of sex, age, or education. Further, it appears unlikely that these factors will be 
relevant in the derivation of optimal psychosis-risk prediction algorithms, based on positive 
symptom ratings at baseline. While similar results have been published from other research 
groups, replication is important, particularly in light of the variation in inclusion and 
exclusion criteria across studies that affect the demographic characteristics of the different 
cohorts (e.g. mean age and education values).
Nonetheless, this remains an empirical question that can be addressed in future studies from 
the NAPLS project when complete follow-up data are available. At that point, it will be 
possible to examine potential moderating effects of demographic factors on the prediction of 
conversion to psychosis based on both clinical symptoms and biomarkers.
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Table 1
Demographic and characteristics and baseline SIPS symptom scores for CHR sample.
Variable CHR (n = 356)
Age (mean ± SD) 18.9 ± 4.2
  Age range 12–35 years
  N < 18 years 155
Sex (n, %)
  Male 208 (58.4%)
  Female 148 (41.6%)
Years of education (mean ± SD)
  Male 11.6 ± 2.5
  Female 11.5 ± 2.9
  Total 11.6 ± 2.6
SOPS P1 symptoms (mean ± SD) 3.31 ± 1.4
SOPS P2 symptoms (mean ± SD) 2.93 ± 1.5
SOPS P3 symptoms (mean ± SD) 1.0 ± 1.3
SOPS P4 symptoms (mean ± SD) 2.9 ± 1.5
SOPS P5 symptoms (mean ± SD) 1.8 ± 1.5
SOPS P total (mean ± SD) 12.0 ± 4.1
Medication (n on meds, %)
  Antipsychotics 62 (18%)
  Antidepressants 94 (28%)
  Stimulants 18 (5%)
  Mood stabilizers 12 (4%)
Note. P1 = unusual thought content; P2 = suspiciousness; P3 = grandiosity; P4 = perceptual abnormalities; P5 = disorganized communication.
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